Approval of Upadacitinib in Pediatric Patients with Active Polyarticular Juvenile Idiopathic Arthritis or Active Psoriatic Arthritis: A Regulatory Perspective

Documenti analoghi

• Model‐Informed Drug Development‐Based Approval of Intravenous Secukinumab for the Treatment of Adult Patients with Active Psoriatic Arthritis, Active Ankylosing Spondylitis, and Active Non‐Radiographic Axial Spondyloarthritis
  di: Dipak S. Pisal, et al.
  Pubblicazione: (2024)
• A Meta‐Analysis of the Safety and Immunogenicity of Pharmacokinetic Similarity Studies and Comparative Clinical Studies
  di: Ping Ji, et al.
  Pubblicazione: (2024)
• Comparison of Analysis of Covariance and Analysis of Variance in Pharmacokinetic Similarity Studies
  di: Brett A. Martini, et al.
  Pubblicazione: (2025)
• Extrapolation of Upadacitinib Efficacy in Juvenile Idiopathic Arthritis Leveraging Pharmacokinetics, Exposure–Response Models, and Real‐World Patient Data
  di: Yuli Qian, et al.
  Pubblicazione: (2024)
• Model‐Informed Drug Development‐Based Bridging from Subcutaneous to Intravenous Secukinumab Dosing: Approval in Psoriatic Arthritis and Axial Spondyloarthritis
  di: Thomas Dumortier, et al.
  Pubblicazione: (2025)